GO:0051145 smooth muscle cell differentiation: Molecular Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051145 describes the biological process by which an unspecialized cell acquires the specialized features of a smooth muscle cell, which lacks transverse striations and is almost always involuntary.
• Vascular smooth muscle cell (VSMC) differentiation is controlled by a network of transcription factors, including myocardin, SRF, and KLF4, that integrate extracellular cues into a contractile gene program.
• Phenotypic modulation, the reversible switch between contractile and synthetic states, is central to vascular disease and is regulated by transcriptional, epigenetic, and RNA-binding mechanisms.
• Human stem and progenitor cells can be directed to differentiate into smooth muscle cells in vitro, providing tractable models to dissect molecular mechanisms and to test therapeutic hypotheses.
• Premature cell senescence and RNA-binding proteins such as RBPMS have emerged as key regulators of smooth muscle cell differentiation and vascular remodeling.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable causal testing of candidate regulators of smooth muscle cell differentiation.
Description
Smooth muscle cell differentiation (GO:0051145) is the developmental process in which a relatively unspecialized cell acquires the specialized features of a smooth muscle cell, a cell type that lacks transverse striations and is almost always involuntary. This process is fundamental to the formation and maintenance of hollow organs, including blood vessels, the gastrointestinal tract, and the respiratory tract, where contractile smooth muscle cells regulate tone, motility, and flow. In the vasculature, smooth muscle cell differentiation is not a terminal, irreversible event; rather, mature smooth muscle cells retain remarkable plasticity and can undergo phenotypic modulation between contractile and synthetic states in response to injury or disease. Understanding the molecular regulation of smooth muscle cell differentiation is therefore central to vascular biology and to the pathogenesis of atherosclerosis, restenosis, and hypertension. Research over the past two decades has defined a core transcriptional program that drives smooth muscle cell differentiation, centered on serum response factor (SRF) and its coactivator myocardin, which together activate contractile genes such as ACTA2, MYH11, and CNN1. This program is antagonized by factors such as KLF4 and modulated by extracellular signals, including TGF-beta and Notch, that converge on chromatin and RNA-processing machinery. In parallel, stem and progenitor cell-based models have been developed to study human smooth muscle cell differentiation in vitro, enabling mechanistic dissection and drug testing. Despite this progress, key questions remain about how smooth muscle cell differentiation is initiated, maintained, and lost in disease. Recent work has implicated premature cell senescence and RNA-binding proteins such as RBPMS in the phenotypic modulation of vascular smooth muscle cells and in resistance to re-differentiation. These findings underscore the need for precise, causal experiments using CRISPR-based genome editing to test the role of individual genes in smooth muscle cell differentiation and vascular remodeling.
smooth muscle cell differentiation At A Glance
| GO ID | GO:0051145 |
|---|---|
| GO term | smooth muscle cell differentiation |
| Ontology | biological_process |
| Synonym | nonstriated muscle cell differentiation |
| Definition | The process in which a relatively unspecialized cell acquires specialized features of a smooth muscle cell; smooth muscle lacks transverse striations in its constituent fibers and are almost always involuntary. |
| Major function | Generation and maintenance of contractile smooth muscle cells in hollow organs and blood vessels, with reversible phenotypic modulation in response to injury and disease. |
| Key regulators | SRF, myocardin (MYOCD), KLF4, TGF-beta signaling, and RNA-binding proteins such as RBPMS. |
| Model systems | Primary vascular smooth muscle cells, human stem/progenitor cell differentiation cultures, and genetically engineered mouse models. |
| Disease relevance | Atherosclerosis, restenosis, hypertension, and other vascular proliferative diseases. |
What Is GO:0051145?
GO:0051145, smooth muscle cell differentiation, is the biological process in which a relatively unspecialized cell acquires the specialized features of a smooth muscle cell. Smooth muscle cells are characterized by the absence of transverse striations in their constituent fibers and are almost always involuntary. This term encompasses the transcriptional, morphological, and functional changes that convert a progenitor or modulated cell into a contractile, smooth-muscle-like state, as well as the dynamic phenotypic transitions that smooth muscle cells can undergo in development and disease.
Why Is smooth muscle cell differentiation Important in Cell Biology?
Smooth muscle cell differentiation is essential for the development and function of hollow organs and blood vessels, and its dysregulation underlies major human diseases. In the vasculature, the balance between contractile and synthetic smooth muscle cell phenotypes determines vessel tone, stability, and response to injury; loss of the contractile program and increased proliferation contribute to atherosclerosis, restenosis, and hypertension. Because smooth muscle cells retain phenotypic plasticity, understanding the molecular switches that control differentiation could reveal therapeutic targets for vascular disease. Moreover, the ability to direct stem and progenitor cells toward smooth muscle lineages has implications for regenerative medicine and tissue engineering. Finally, precise CRISPR-based models are needed to establish causal roles for candidate genes in smooth muscle cell differentiation, moving beyond correlative observations.
• Smooth muscle cell differentiation is required for the normal development and function of blood vessels, gut, airways, and other hollow organs.
• Loss of the contractile smooth muscle cell phenotype and increased synthetic/proliferative activity contribute to atherosclerosis and restenosis.
• Phenotypic modulation of smooth muscle cells is a reversible process, making it a dynamic and therapeutically relevant target.
• Transcriptional regulators such as SRF, myocardin, and KLF4 are central to the contractile gene program and are implicated in vascular disease.
• RNA-binding proteins such as RBPMS control smooth muscle cell-driven vascular remodeling in atherosclerosis and injury.
• Premature cell senescence promotes phenotypic modulation and resistance to re-differentiation, linking aging to vascular pathology.
• Human stem/progenitor cell models enable the study of human smooth muscle cell differentiation and drug responses.
• CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of candidate genes in smooth muscle cell differentiation.
• Smooth muscle cell differentiation research informs regenerative strategies for vascular and hollow organ repair.
• Understanding smooth muscle cell differentiation provides a framework for identifying novel therapeutic targets in vascular proliferative diseases.
What Happens During smooth muscle cell differentiation?
Initiation and transcriptional priming
In simple terms: The cell starts turning on the first smooth-muscle-specific genes.
Smooth muscle cell differentiation begins when extracellular cues, including TGF-beta superfamily ligands and mechanical signals, activate intracellular signaling cascades that converge on transcription factors. Serum response factor (SRF) binds CArG box elements in the promoters of smooth muscle contractile genes and, together with its coactivator myocardin (MYOCD), initiates a transcriptional program that defines the smooth muscle lineage. This early phase is characterized by the expression of intermediate markers and the remodeling of chromatin at contractile gene loci, priming the cell for full differentiation.
Establishment of the contractile gene program
In simple terms: The cell builds the machinery that lets it contract.
As differentiation proceeds, the SRF-myocardin complex drives high-level expression of contractile proteins, including smooth muscle alpha-actin (ACTA2), smooth muscle myosin heavy chain (MYH11), calponin (CNN1), and SM22 alpha (TAGLN). These proteins assemble into the contractile apparatus and confer the ability to generate force. The coordinated expression of this gene set is a hallmark of mature, contractile smooth muscle cells and is often used experimentally to define the differentiated state.
Phenotypic modulation and reversibility
In simple terms: Smooth muscle cells can switch between a contracting state and a growing/repair state.
Unlike many terminally differentiated cells, smooth muscle cells retain the ability to modulate their phenotype. In response to injury or disease, contractile smooth muscle cells can downregulate contractile markers and adopt a synthetic, proliferative, and migratory phenotype, a process known as phenotypic modulation. This switch is reversible, and re-differentiation can occur when the stimulus is removed, although premature senescence and other factors can impair re-differentiation. Phenotypic modulation is central to vascular remodeling and is regulated by transcription factors such as KLF4 and by RNA-binding proteins such as RBPMS.
Epigenetic and post-transcriptional control
In simple terms: Chemical tags on DNA and RNA help lock in or loosen the smooth muscle identity.
Smooth muscle cell differentiation is accompanied by changes in DNA methylation, histone modifications, and chromatin accessibility at contractile gene loci. In addition, post-transcriptional mechanisms, including alternative splicing and RNA-binding protein activity, fine-tune the expression of contractile genes. For example, the RNA-binding protein RBPMS has been shown to inhibit smooth muscle cell-driven vascular remodeling, highlighting the importance of post-transcriptional control in this process. These layers of regulation ensure that smooth muscle cell differentiation is both robust and adaptable.
Integration with senescence and aging
In simple terms: Aging and cell aging can push smooth muscle cells away from the differentiated state.
Recent evidence indicates that premature cell senescence promotes vascular smooth muscle cell phenotypic modulation and resistance to re-differentiation. Senescent smooth muscle cells acquire a pro-inflammatory secretory phenotype and lose contractile gene expression, contributing to vascular pathology. This link between senescence and differentiation state suggests that interventions targeting senescence pathways might help preserve or restore the contractile phenotype in aging vessels.
Key Genes Involved in GO:0051145 smooth muscle cell differentiation
The following genes and proteins are central to the regulation and execution of smooth muscle cell differentiation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MYOCD (myocardin) | Transcriptional coactivator of SRF that drives contractile gene expression | Master regulator of smooth muscle cell differentiation; target for gain- and loss-of-function studies |
| SRF | Transcription factor binding CArG boxes in smooth muscle genes | Central node integrating signaling inputs; knockout is lethal, requiring conditional models |
| ACTA2 | Smooth muscle alpha-actin, a contractile protein and early differentiation marker | Mutations cause vascular diseases; widely used as a differentiation readout |
| MYH11 | Smooth muscle myosin heavy chain, a contractile protein | Late differentiation marker; mutations associated with aortic disease |
| CNN1 | Calponin, a contractile apparatus protein | Marker of mature smooth muscle cells; used to assess differentiation state |
| TAGLN (SM22 alpha) | Actin-binding protein enriched in smooth muscle | Common marker for smooth muscle cell differentiation in vitro and in vivo |
| KLF4 | Transcription factor that antagonizes the contractile program | Promotes phenotypic modulation; knockout delays injury-induced modulation |
| KLF5 | Transcription factor involved in smooth muscle proliferation and differentiation | Modulates vascular remodeling; potential therapeutic target |
| RBPMS | RNA-binding protein that inhibits smooth muscle cell-driven vascular remodeling | Emerging regulator of differentiation and disease; target for RNA-level studies |
| TGFB1 | Cytokine that promotes smooth muscle cell differentiation | Exogenous TGF-beta is used to induce differentiation in vitro |
| NOTCH receptors | Signaling pathway that influences smooth muscle differentiation | Context-dependent roles in development and disease |
| PDGF-BB | Growth factor that promotes synthetic phenotype and inhibits differentiation | Used experimentally to induce phenotypic modulation |
| MYOCD-related MRTF-A | Coactivator that can substitute for myocardin in some contexts | Modulates SRF-dependent transcription; studied in knockout models |
| ELN (elastin) | Extracellular matrix protein important for vessel wall structure | Its expression is linked to smooth muscle differentiation and vascular disease |
| COL1A1 | Collagen type I, a matrix protein produced by synthetic smooth muscle cells | Marker of synthetic phenotype; used to assess modulation |
| CDKN2A (p16) | Cell cycle inhibitor and senescence marker | Linked to premature senescence and impaired re-differentiation |
| LMOD1 | Leiomodin 1, an actin-binding protein in smooth muscle | Mutations associated with megacystis-microcolon syndrome; differentiation marker |
| MYLK | Myosin light chain kinase, regulates smooth muscle contraction | Functional readout of contractile differentiation |
How Is smooth muscle cell differentiation Regulated?
Smooth muscle cell differentiation is regulated at multiple levels. Extracellular signals, including TGF-beta, Notch, and mechanical stretch, activate intracellular kinases and transcription factors that converge on SRF and its coactivators. Transcriptional regulation involves the interplay of activators such as myocardin and repressors such as KLF4, which compete for SRF binding and modulate chromatin state. Epigenetic mechanisms, including DNA methylation and histone acetylation, establish and maintain the contractile gene expression program. Post-transcriptional regulation by RNA-binding proteins such as RBPMS and by microRNAs further tunes differentiation and phenotypic modulation. In addition, cellular senescence pathways, including p16/CDKN2A, can promote phenotypic modulation and resistance to re-differentiation, linking aging to loss of the differentiated state.
smooth muscle cell differentiation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ACTA2 | Thoracic aortic aneurysm and dissection; smooth muscle dysfunction | Knock-in of patient mutations in vascular smooth muscle cells or mouse models |
| MYH11 | Aortic aneurysm; impaired contractile function | Knockout or point-mutation models in human stem cell-derived smooth muscle cells |
| RBPMS | Atherosclerosis and vascular injury; regulation of smooth muscle remodeling | Knockout and overexpression in primary vascular smooth muscle cells and injury models |
| CDKN2A (p16) | Premature senescence; resistance to re-differentiation | Overexpression and knockout in smooth muscle cell cultures and aged mouse models |
| KLF4 | Phenotypic modulation in atherosclerosis and restenosis | Conditional knockout and overexpression in vascular smooth muscle cells |
Atherosclerosis and vascular remodeling
Atherosclerosis is characterized by the accumulation of lipids and inflammatory cells in the arterial wall, accompanied by phenotypic modulation of vascular smooth muscle cells from a contractile to a synthetic, proliferative state. This switch contributes to plaque formation, fibrous cap stability, and lesion progression. RNA-binding proteins such as RBPMS have been shown to inhibit smooth muscle cell-driven vascular remodeling in atherosclerosis and after vascular injury, suggesting that post-transcriptional control of differentiation is a therapeutic node. Premature senescence of smooth muscle cells further promotes phenotypic modulation and resistance to re-differentiation, exacerbating disease.
Restenosis after angioplasty
Restenosis is the re-narrowing of a blood vessel after angioplasty or stenting, driven largely by the proliferation and migration of synthetic smooth muscle cells. Loss of the contractile differentiation program is a key step in this process, and factors that promote re-differentiation or inhibit phenotypic modulation are being explored as therapeutic strategies. Experimental models of vascular injury are widely used to study the role of specific genes in restenosis.
Hypertension and vascular stiffness
Hypertension is associated with changes in smooth muscle cell differentiation and increased vascular stiffness. Alterations in the expression of contractile proteins and extracellular matrix components contribute to altered vessel tone and remodeling. Understanding how differentiation state is regulated may inform new approaches to treat hypertension and related vascular disorders.
Developmental and genetic disorders of smooth muscle
Mutations in genes encoding smooth muscle contractile proteins, such as ACTA2 and MYH11, cause inherited vascular diseases, including thoracic aortic aneurysms and dissections. These conditions highlight the importance of proper smooth muscle cell differentiation for vascular integrity. In addition, disorders affecting smooth muscle in the gut and other organs can result from defects in differentiation or function.
From smooth muscle cell differentiation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for smooth muscle cell differentiation? | CRISPR knockout in human stem/progenitor cell-derived smooth muscle cells or primary vascular smooth muscle cells |
| Does a specific point mutation alter contractile gene expression? | CRISPR point mutation (base editing or HDR) in a smooth muscle cell line or primary cells |
| Does a risk variant affect differentiation? | Knock-in of the variant allele in a reporter cell line or iPSC-derived smooth muscle cells |
| Where and when is a protein expressed during differentiation? | Tagged knock-in (e.g., GFP or HA) in stem cells or mice |
| Does overexpression of a factor drive or inhibit differentiation? | CRISPR activation or lentiviral overexpression in progenitor cells |
| What genes are essential for smooth muscle cell differentiation? | Genome-wide CRISPR knockout library screening in a differentiation-competent cell model |
How to Study the smooth muscle cell differentiation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify contractile and synthetic gene signatures during differentiation |
| ChIP-seq | Transcription factor binding and histone modifications | Map SRF/myocardin binding and epigenetic changes at contractile loci |
| ATAC-seq | Chromatin accessibility | Detect regulatory regions that open or close during differentiation |
| Immunofluorescence | Protein expression and localization | Visualize smooth muscle markers (ACTA2, MYH11) in cultured cells and tissues |
| Collagen gel contraction assay | Functional contractility | Assess contractile capacity of differentiated smooth muscle cells |
| Mass spectrometry proteomics | Protein abundance and modifications | Quantify contractile protein expression during differentiation |
| Flow cytometry | Cell surface markers and differentiation efficiency | Sort and quantify smooth muscle-like cells from differentiation cultures |
| Vascular injury models | In vivo phenotypic modulation and remodeling | Test gene function in restenosis and atherosclerosis |
In vitro differentiation assays
Human stem and progenitor cells can be induced to differentiate into smooth muscle cells using defined media supplemented with TGF-beta and other factors. These cultures are used to assess contractile gene expression by quantitative PCR, immunoblotting, and immunofluorescence for markers such as ACTA2, MYH11, and CNN1. Differentiation efficiency can be quantified by flow cytometry or high-content imaging.
Transcriptomic and epigenomic profiling
RNA sequencing (RNA-seq) provides a global view of gene expression changes during smooth muscle cell differentiation, revealing contractile and synthetic gene signatures. Chromatin immunoprecipitation sequencing (ChIP-seq) for SRF, myocardin, and histone modifications identifies regulatory elements and epigenetic changes. Assay for transposase-accessible chromatin with sequencing (ATAC-seq) maps open chromatin regions that change during differentiation.
Proteomic and functional assays
Mass spectrometry-based proteomics can quantify contractile protein abundance and post-translational modifications during differentiation. Functional assays, including collagen gel contraction and calcium imaging, measure the contractile capacity of differentiated smooth muscle cells. These methods complement gene expression data to confirm the functional differentiated state.
In vivo models of vascular remodeling
Animal models of vascular injury, such as carotid artery ligation or balloon angioplasty, are used to study smooth muscle cell phenotypic modulation and re-differentiation in vivo. Lineage-tracing and conditional knockout mice allow researchers to track smooth muscle cell fate and test gene function in a physiological context. These models are essential for translating in vitro findings to disease mechanisms.
How CRISPR Can Be Used to Study GO:0051145 smooth muscle cell differentiation
Knockout
CRISPR knockout is used to delete candidate genes in smooth muscle cell models to test whether they are required for differentiation or phenotypic modulation. For essential genes, inducible or conditional knockout systems allow temporal control. Knockout of transcription factors such as MYOCD or SRF can abolish contractile gene expression, while knockout of repressors such as KLF4 may enhance differentiation. These experiments provide causal evidence linking genes to smooth muscle cell differentiation.
Point Mutation
CRISPR point mutation, achieved through base editing or homology-directed repair, introduces specific disease-associated variants into the genome. This approach is valuable for studying how mutations in genes such as ACTA2 or MYH11 affect smooth muscle cell differentiation and contractile function. Point-mutation models help distinguish pathogenic variants from benign polymorphisms and can reveal allele-specific effects.
Knock-in
Knock-in strategies are used to insert reporter tags (e.g., GFP, luciferase) or to humanize a locus by replacing a mouse gene with its human ortholog. Tagged knock-in of contractile proteins allows real-time monitoring of differentiation in live cells and tissues. Knock-in of risk variants or regulatory elements can also be used to study their impact on smooth muscle cell differentiation.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression enables gain-of-function studies to determine whether a gene is sufficient to drive or inhibit smooth muscle cell differentiation. Overexpression of myocardin, for example, can induce contractile gene expression in non-smooth muscle cells, while overexpression of KLF4 can promote phenotypic modulation. These approaches complement loss-of-function studies to establish causality.
How EDITGENE Supports smooth muscle cell differentiation Research
Researchers studying smooth muscle cell differentiation-related genes often need to determine whether a candidate gene is causally involved in the process or merely correlated with it. Establishing causality requires precise genetic manipulation, ideally in relevant human cell models. EDITGENE provides a suite of CRISPR-based services designed to accelerate this discovery pipeline, from knockout to knock-in and library screening.
Contact EDITGENE today to design your custom CRISPR model for smooth muscle cell differentiation research.
Frequently Asked Questions About smooth muscle cell differentiation
What is GO:0051145 smooth muscle cell differentiation?
GO:0051145 is the biological process in which a relatively unspecialized cell acquires the specialized features of a smooth muscle cell, which lacks transverse striations and is almost always involuntary.
What genes are involved in smooth muscle cell differentiation?
Key genes include MYOCD (myocardin), SRF, ACTA2, MYH11, CNN1, TAGLN, KLF4, KLF5, and RBPMS, among others.
What are the markers of smooth muscle cell differentiation?
Common markers include smooth muscle alpha-actin (ACTA2), smooth muscle myosin heavy chain (MYH11), calponin (CNN1), and SM22 alpha (TAGLN).
How is smooth muscle cell differentiation regulated?
It is regulated by transcription factors such as SRF and myocardin, repressors such as KLF4, extracellular signals like TGF-beta, epigenetic modifications, and RNA-binding proteins such as RBPMS.
What is phenotypic modulation in smooth muscle cells?
Phenotypic modulation is the reversible switch between a contractile, differentiated state and a synthetic, proliferative state that occurs in response to injury or disease.
How do you study smooth muscle cell differentiation in vitro?
Researchers use stem/progenitor cell differentiation cultures, primary vascular smooth muscle cells, and assays such as RNA-seq, immunofluorescence, and collagen gel contraction.
What diseases are linked to smooth muscle cell differentiation?
Atherosclerosis, restenosis, hypertension, and inherited vascular diseases such as thoracic aortic aneurysm are linked to altered smooth muscle cell differentiation.
Can CRISPR be used to study smooth muscle cell differentiation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of genes involved in smooth muscle cell differentiation.
What is the role of RBPMS in smooth muscle cells?
RBPMS is an RNA-binding protein that inhibits smooth muscle cell-driven vascular remodeling in atherosclerosis and vascular injury.
How does senescence affect smooth muscle cell differentiation?
Premature cell senescence promotes phenotypic modulation and resistance to re-differentiation, contributing to vascular pathology.
Conclusion
GO:0051145 smooth muscle cell differentiation is a dynamic and clinically important biological process that governs the formation and plasticity of smooth muscle cells in hollow organs and blood vessels. Its dysregulation is central to atherosclerosis, restenosis, hypertension, and inherited vascular diseases. Advances in stem cell models, transcriptomics, and CRISPR-based genome editing are providing new tools to dissect the molecular mechanisms that control differentiation and phenotypic modulation. By combining precise genetic models with functional assays, researchers can establish causal roles for candidate genes and identify new therapeutic targets for vascular disease.
References
- 1. Owens GK et al.. 2004. Molecular regulation of vascular smooth muscle cell differentiation in development and disease.. Physiol Rev 84(3):767-801 PMID: 15269336
- 2. Kaistha A et al.. 2025. Premature cell senescence promotes vascular smooth muscle cell phenotypic modulation and resistance to re-differentiation.. Cardiovasc Res 121(9):1448-1463 PMID: 40493738
- 3. Shi N et al.. 2016. Smooth Muscle Cell Differentiation: Model Systems, Regulatory Mechanisms, and Vascular Diseases.. J Cell Physiol 231(4):777-87 PMID: 26425843
- 4. Steinbach SK et al.. 2016. Vascular smooth muscle cell differentiation from human stem/progenitor cells.. Methods 101:85-92 PMID: 26678794
- 5. Khachigian LM et al.. 2022. Transcriptional regulation of vascular smooth muscle cell proliferation, differentiation and senescence: Novel targets for therapy.. Vascul Pharmacol 146:107091 PMID: 35896140
- 6. Du J et al.. 2025. The RNA-binding protein RBPMS inhibits smooth muscle cell-driven vascular remodeling in atherosclerosis and vascular injury.. Proc Natl Acad Sci U S A 122(9):e2415933122 PMID: 39999164
- 7. Xie C et al.. 2011. Smooth muscle cell differentiation in vitro: models and underlying molecular mechanisms.. Arterioscler Thromb Vasc Biol 31(7):1485-94 PMID: 21677291
- 8. Xiao Q et al.. 2010. The mechanism of stem cell differentiation into smooth muscle cells.. Thromb Haemost 104(3):440-8 PMID: 20539914
